Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. VABYSMO (faricimab)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

VABYSMO (faricimab)

Medicine - Posted on Mar 05 2025
Active substance (DCI)
  • faricimab
history (4)
  • 2/12/25

    VABYSMO (faricimab) - Retrofoveal age-related macular degeneration, diabetic macular oedema, macular oedema secondary to branch retinal

    Summary of opinion Favourable opinion for reimbursement in: neovascular (wet) retrofoveal age-related macular degeneration (...
    CAV :
    54321
    icône flèche
  • 12/18/24

    VABYSMO (faricimab) - Macular oedema secondary to branch retinal vein occlusion (BRVO)

    Summary of opinion Favourable opinion for reimbursement in the treatment of adult patients with reduced visual acuity due to...
    CAV :
    54321
    icône flèche
  • 1/18/23

    VABYSMO (faricimab) - Diabetic macular oedema (DME)

    New indication. Key points Favourable opinion for reimbursement only in “the treatment of adult patients with visual impairm...
    CAV :
    54321
    icône flèche
  • 1/18/23

    VABYSMO (faricimab) - Neovascular (wet) retrofoveal age-related macular degeneration (AMD)

    New indication. Key points Favourable opinion for reimbursement “the treatment of neovascular (wet) retrofoveal age-related ...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • S01LA09
Manufacturer
ROCHE
Presentation

VABYSMO 120 mg/mL, solution injectable
1 flacon contenant 0,24 mL de solution (CIP : 34009 302 625 9 7)

VABYSMO 120 mg/mL, solution injectable en seringue préremplie
1 seringue préremplie (verre) de 0,175 mL avec une aiguille d’injection avec filtre (CIP : 34009 303 092 1 6)

All our publications
    Diabetes mellitus Drug therapy Eye diseases Geriatrics

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
5RVNju8SmxXngJXR